Sucralfate
When ATH:
A02BX02
Characteristic.
White hygroscopic amorphous powder. The easily soluble in dilute acids, practically insoluble in water.
Pharmacological action.
Antacidnoe, absorbent, enveloping, gastroprotective, protivoyazvennoe.
Application.
Peptic ulcer and duodenal (Prevention and treatment), damage to the gastrointestinal mucosa, due to stress or NSAIDs (Prevention and treatment), hyperacid gastritis, gastroesophageal reflux disease, hyperphosphatemia in patients with uremia, hemodialysis.
Contraindications.
Hypersensitivity, Dysphagia, or obstruction of the digestive tract, bleeding from the gastrointestinal tract, renal failure, pregnancy, childhood (to 4 years).
Side effects.
Dyspepsia, constipation or diarrhea, pain (in a stomach, back, headache), dizziness, drowsiness, dryness of the mouth, nausea, skin rash and itching, hives.
Cooperation.
It decreases absorption of fluoroquinolones (Ciprofloxacin, norfloxacin, ofloxacin), tetracycline, teofillina, phenytoin. Increases (mutually) drug toxicity, aluminum-containing (especially in patients with renal insufficiency). Active antacid reduces, histamine H2-receptors.
Dosing and Administration.
Inside, 30-40 minutes before meals and at bedtime, without chewing, drinking plenty of water; adults - 0.5-1 g 4 once a day (before breakfast, dinner, dinner and overnight) or 1 g morning and evening; The maximum daily dose - 8 g; Course of treatment - 4-6 weeks, if necessary - up 12 Sun.
Children - 0,5 g 4 once a day.
Precautions.
In patients with renal failure is necessary to monitor serum aluminum and phosphate - the appearance of sleepiness and seizures may indicate a manifestation of the toxic effects of aluminum. If concomitant use of antacids should be given for 30 minutes before or 30 min after sucralfate. Introduction nasogastric tube may lead to the formation of bezoar with other drugs or solutions for parenteral nutrition (because of the ability to bind to the protein).
Cooperation
| Active substance | Description of interaction |
| Warfarin | FMR: antagonizm. Against the backdrop of sucralfate slows absorption and attenuated effect. |
| Levothyroxine sodium | FKV. Against the backdrop of sucralfate may decrease the absorption, reduction in bioavailability and worsening hypothyroidism; the combined appointment interval between doses should be at least 4 no. |
| Naproxen | FMR. Against the backdrop of sucralfate reduces the absorption of; concomitant use is not recommended. |
| Norfloxacin | FKV. On the background of sucralfate slows absorption and decreases the concentration in the blood and / or urine; the combined appointment interval between doses should be at least 2 no. |
| Ofloxacin | FKV. On the background of sucralfate slows absorption and decreases the concentration in the blood and / or urine; the combined use of the interval between doses should be at least 2 no. |
| Ranitidine | FKV. Against the backdrop of sucralfate may decrease the absorption of; the combined appointment interval between doses should be at least 2 no. |
| Sulpyryd | FKV. Against the backdrop of sucralfate slows down absorption and reduce bioavailability. |
| Theophylline | FKV. Against the background of reduced absorption of sucralfate. |
| Phenytoin | FKV. Against the background of reduced absorption of sucralfate. |
| Ciprofloxacin | FKV. Against the backdrop of sucralfate reduces the absorption of; the combined appointment interval between doses should be at least 2 no. |
